HbA1c performs well in monitoring glucose control even in populations with high prevalence of medical conditions that may alter its reliability: The OPTIMAL observational multicenter study
dc.contributor.author | Niwaha, AJ | |
dc.contributor.author | Rodgers, LR | |
dc.contributor.author | Greiner, R | |
dc.contributor.author | Balungi, PA | |
dc.contributor.author | Mwebaze, R | |
dc.contributor.author | McDonald, TJ | |
dc.contributor.author | Hattersley, AT | |
dc.contributor.author | Shields, BM | |
dc.contributor.author | Nyirenda, MJ | |
dc.contributor.author | Jones, AG | |
dc.date.accessioned | 2021-10-06T10:15:43Z | |
dc.date.issued | 2021-09-17 | |
dc.description.abstract | Introduction: The utility of HbA1c (glycosylated hemoglobin) to estimate glycemic control in populations of African and other low-resource countries has been questioned because of high prevalence of other medical conditions that may affect its reliability. Using continuous glucose monitoring (CGM), we aimed to determine the comparative performance of HbA1c, fasting plasma glucose (FPG) (within 5 hours of a meal) and random non-fasting glucose (RPG) in assessing glycemic burden. Research design and methods: We assessed the performance of HbA1c, FPG and RPG in comparison to CGM mean glucose in 192 Ugandan participants with type 2 diabetes. Analysis was undertaken in all participants, and in subgroups with and without medical conditions reported to affect HbA1c reliability. We then assessed the performance of FPG and RPG, and optimal thresholds, in comparison to HbA1c in participants without medical conditions thought to alter HbA1c reliability. Results: 32.8% (63/192) of participants had medical conditions that may affect HbA1c reliability: anemia 9.4% (18/192), sickle cell trait and/or hemoglobin C (HbC) 22.4% (43/192), or renal impairment 6.3% (12/192). Despite high prevalence of medical conditions thought to affect HbA1c reliability, HbA1c had the strongest correlation with CGM measured glucose in day-to-day living (0.88, 95% CI 0.84 to 0.91), followed by FPG (0.82, 95% CI 0.76 to 0.86) and RPG (0.76, 95% CI 0.69 to 0.81). Among participants without conditions thought to affect HbA1c reliability, FPG and RPG had a similar diagnostic performance in identifying poor glycemic control defined by a range of HbA1c thresholds. FPG of ≥7.1 mmol/L and RPG of ≥10.5 mmol/L correctly identified 78.2% and 78.8%, respectively, of patients with an HbA1c of ≥7.0%. Conclusions: HbA1c is the optimal test for monitoring glucose control even in low-income and middle-income countries where medical conditions that may alter its reliability are prevalent; FPG and RPG are valuable alternatives where HbA1c is not available. | en_GB |
dc.description.sponsorship | National Institute for Health Research (NIHR) | en_GB |
dc.identifier.citation | Vol. 9, No. 1, article e002350 | en_GB |
dc.identifier.doi | 10.1136/bmjdrc-2021-002350 | |
dc.identifier.grantnumber | 17/63/131 | en_GB |
dc.identifier.uri | http://hdl.handle.net/10871/127370 | |
dc.language.iso | en | en_GB |
dc.publisher | BMJ Publishing Group | en_GB |
dc.rights | © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. | en_GB |
dc.title | HbA1c performs well in monitoring glucose control even in populations with high prevalence of medical conditions that may alter its reliability: The OPTIMAL observational multicenter study | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2021-10-06T10:15:43Z | |
dc.identifier.issn | 2052-4897 | |
dc.description | This is the final version. Available from BMJ Publishing via the DOI in this record. | en_GB |
dc.description | Data availability statement: Data are available upon reasonable request. | en_GB |
dc.identifier.journal | BMJ Open Diabetes Research and Care | en_GB |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | en_GB |
dcterms.dateAccepted | 2021-08-22 | |
exeter.funder | ::National Institute for Health Research (NIHR) | en_GB |
exeter.funder | ::National Institute for Health Research (NIHR) | en_GB |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2021-09-17 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2021-10-06T10:11:49Z | |
refterms.versionFCD | VoR | |
refterms.dateFOA | 2021-10-06T10:15:50Z | |
refterms.panel | A | en_GB |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/
This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.